At the time of writing, Cidara Therapeutics Inc [CDTX] stock is trading at $67.49, up 3.78%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CDTX shares have gain 6.20% over the last week, with a monthly amount glided 4.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citizens JMP started tracking the stock with Mkt Outperform rating on March 12, 2025, and set its price target to $46. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $34 on December 13, 2024. Guggenheim initiated its recommendation with a Buy and recommended $33 as its price target on November 08, 2024. H.C. Wainwright upgraded its rating to Buy for this stock on August 14, 2024, but kept the price target unchanged to $24.
For the past year, the stock price of Cidara Therapeutics Inc fluctuated between $10.14 and $66.94. Currently, Wall Street analysts expect the stock to reach $57.5 within the next 12 months. Cidara Therapeutics Inc [NASDAQ: CDTX] shares were valued at $67.49 at the most recent close of the market. An investor can expect a potential drop of -14.8% based on the average CDTX price forecast.
Analyzing the CDTX fundamentals
According to Cidara Therapeutics Inc [NASDAQ:CDTX], the company’s sales were 0.00M for trailing twelve months, which represents an -100.00% plunge. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.4 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 64.31 points at the first support level, and at 61.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 70.02, and for the 2nd resistance point, it is at 72.54.
Ratios To Look Out For
It is important to note that Cidara Therapeutics Inc [NASDAQ:CDTX] has a current ratio of 16.45. Also, the Quick Ratio is 16.45, while the Cash Ratio stands at 15.8.
Transactions by insiders
Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., Director, that happened on Jun 26 ’25 when 2.27 million shares were purchased. Director, Mineo Chrysa completed a deal on Jun 02 ’25 to buy 2270.0 shares. Meanwhile, Director Mineo Chrysa bought 1050.0 shares on Jun 03 ’25.
